



# Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal *versus* nasopharyngeal swab

*To the Editor:*

Antigen-detecting rapid diagnostic tests (Ag-RDTs) are likely to play a substantial role in innovative testing strategies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2]. Currently, most Ag-RDTs require nasopharyngeal (NP) sampling performed by qualified healthcare professionals. Nasal sampling would enable scaling of antigen testing strategies. The term nasal sampling is often not used uniformly, but can be differentiated as either anterior nasal sampling (entire absorbent tip of the swab, usually 1 to 1.5 cm, inserted into nostril), and nasal mid-turbinate (as described below) [3].

We conducted a prospective diagnostic accuracy study with the objective to directly compare the performance of professional-collected nasal mid-turbinate (NMT) *versus* NP swab, using a World Health Organization (WHO)-listed SARS-CoV-2 Ag-RDT. The reference standard was RT-PCR collected from a combined NP/oropharyngeal (OP) swab. The study was continued until 30 positive NP swab samples according to Ag-RDT were obtained, which is the minimum recommended by the WHO Emergency Use Listing Procedure to demonstrate sample type equivalency [4]. This manufacturer-independent study was conducted in partnership with the Foundation of Innovative New Diagnostics, the WHO collaborating centre for coronavirus disease 2019 (COVID-19) diagnostics.

Adults at high risk for SARS-CoV-2 infection according to clinical suspicion who attended the ambulatory SARS-CoV-2 testing facility of Charité University Hospital Berlin, Germany, were enrolled from 11 to 18 November 2020. Participants were excluded if either of the swabs for the Ag-RDT or the RT-PCR reference standard could not be collected.

Participants had to blow once the nose with a tissue. Afterwards, a NMT sample was collected on both sides of the nose, using the specific nasal swab provided in the test kit of the manufacturer, according to the instructions for use, which also correspond to the US Centers for Disease Control and Prevention instructions [3]. Briefly, while tilting the patient's head back 70 degrees, the swab was inserted about 2 cm into each nostril, parallel to the palate until resistance was met at turbinates, then rotated 3–4 times against the nasal walls. Subsequently, a separate NP-swab (provided in the manufacturer test kit) for the Ag-RDT and a combined OP/NP-swab (eSwab from Copan placed in 1 mL Amies medium) as per institutional recommendations for RT-PCR were taken from different sides of the nose.

The Ag-RDT evaluated was the STANDARD Q COVID-19 Ag Test (SD Biosensor, Inc., Gyeonggi-do, Korea; henceforth called STANDARD Q) [5]. Study procedures followed the same process as described in the prior study by LINDNER *et al.* [6]. While the test is commercially available as NP sampling kit, the nasal sampling kit is currently available for “research use only” by the manufacturer. The instructions for use of the two test kits showed differences, with a more elaborate extraction process (stirring the swab at least 10 *versus* five times) and a higher volume of extracted specimen (four *versus* three drops) used for testing of nasal samples.



@ERSpublications

**Professional nasal sampling is a reliable alternative to nasopharyngeal sampling when using a WHO-listed SARS-CoV-2 antigen-detecting rapid test. This less invasive method needs less training to facilitate rapid scaling of testing strategies.** <https://bit.ly/3pEVIUL>

**Cite this article as:** Lindner AK, Nikolai O, Rohardt C, *et al.* Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal *versus* nasopharyngeal swab. *Eur Respir J* 2021; 57: 2004430 [<https://doi.org/10.1183/13993003.04430-2020>].

Of 181 patients invited, 180 (99.4%) consented to participate. One patient was excluded as both swabs for the Ag-RDT could not be obtained. The mean±SD age of participants was 36.2±12.2 years, with 48.0% female and 14.5% having comorbidities. On the day of testing, 96.1% of participants had one or more symptoms consistent with COVID-19. Duration of symptoms at the time of presentation on average was 4.2±2.6 days. Among the 179 participants, 41 (22.9%) tested positive for SARS-CoV-2 by RT-PCR (table 1).

TABLE 1 Antigen-detecting rapid diagnostic test (Ag-RDT) results with a professional-collected nasal mid-turbinate (NMT) swab and nasopharyngeal (NP) swab in RT-PCR positive patients from combined NP/oropharyngeal (OP) swab

Number	NMT swab	NP swab	OP/NP swab RT-PCR		Symptom duration days
	SD Q Ag-RDT	SD Q Ag-RDT	CT value	Viral load*	
1	pos. (+++)	pos. (+++)	16.41 <sup>¶</sup>	9.11	
2	pos. (++)	pos. (+++)	19.25 <sup>#,§</sup>		7
3	pos. (+++)	pos. (+++)	19.82 <sup>#</sup>	8.85	4
4	pos. (++)	pos. (+++)	17.68 <sup>¶</sup>	8.73	1
5	pos. (+++)	pos. (+++)	17.82 <sup>¶</sup>	8.69	3
6	pos. (+++)	pos. (+++)	18.57 <sup>¶</sup>	8.46	4
7	pos. (+++)	pos. (+++)	22.09 <sup>#</sup>	8.17	4
8	pos. (++)	pos. (+++)	19.96 <sup>¶</sup>	8.05	8
9	pos. (++)	pos. (+++)	22.70 <sup>#</sup>	7.99	5
10	pos. (++)	pos. (++)	20.74 <sup>¶</sup>	7.82	3
11	pos. (+++)	pos. (+++)	23.54 <sup>#</sup>	7.75	3
12	pos. (+++)	pos. (+++)	24.09 <sup>#</sup>	7.58	3
13	pos. (+++)	pos. (+++)	24.37 <sup>#</sup>	7.50	2
14	pos. (+++)	pos. (++)	21.83 <sup>¶</sup>	7.50	5
15	pos. (+)	pos. (+++)	24.41 <sup>#</sup>	7.49	2
16	pos. (++)	pos. (+++)	24.62 <sup>#</sup>	7.43	6
17	pos. (+)	neg.	22.42 <sup>¶</sup>	7.32	10
18	pos. (+++)	pos. (+++)	25.38 <sup>#</sup>	7.20	4
19	pos. (+++)	pos. (++)	22.85 <sup>¶</sup>	7.19	5
20	pos. (++)	pos. (+++)	23.05 <sup>¶</sup>	7.13	5
21	pos. (++)	neg.	26.48 <sup>#</sup>	6.87	8
22	pos. (+++)	pos. (++)	24.13 <sup>¶</sup>	6.81	3
23	pos. (+++)	pos. (+++)	24.63 <sup>¶</sup>	6.66	2
24	pos. (+++)	pos. (++)	24.71 <sup>¶</sup>	6.64	3
25	pos. (+++)	pos. (++)	27.84 <sup>#</sup>	6.47	2
26	neg.	neg.	25.55 <sup>¶</sup>	6.39	4
27	pos. (++)	pos. (+++)	28.82 <sup>#</sup>	6.18	5
28	pos. (+++)	pos. (++)	26.64 <sup>¶</sup>	6.07	3
29	neg.	neg.	26.79 <sup>¶</sup>	6.02	3
30	pos. (+++)	pos. (++)	29.87 <sup>#</sup>	5.87	4
31	neg.	neg.	30.91 <sup>#</sup>	5.56	7
32	pos. (+++)	pos. (+++)	29.31 <sup>¶</sup>	5.27	5
33	neg.	neg.	29.84 <sup>¶</sup>	5.12	4
34	pos. (+)	neg.	33.05 <sup>#</sup>	4.93	8
35	pos. (++)	pos. (+)	31.56 <sup>¶</sup>	4.61	5
36	neg.	neg.	34.24 <sup>#</sup>	4.58	6
37	neg.	neg.	34.52 <sup>#</sup>	4.50	9
38	pos. (+)	pos. (++)	34.69 <sup>#</sup>	4.44	
39	pos. (+)	neg.	35.16 <sup>#</sup>	4.31	10
40	neg.	neg.	34.58 <sup>¶</sup>	3.71	7
41	neg.	pos. (+)	35.53 <sup>¶</sup>	3.43	8
<b>Sensitivity</b>	33/41 (80.5%)	30/41 (73.2%)			
<b>Positive percent agreement<sup>f</sup></b>	93.5% [95% CI 79.3–98.2%]				

Cycle threshold (CT) values and viral load (in descending order) of the paired RT-PCR samples are shown, as well as the duration of symptoms per patient. The positive percent agreement between NMT and NP samples on Ag-RDT, and the respective sensitivities compared to RT-PCR are shown. SD Q: STANDARD Q COVID-19 Ag Test (SD Biosensor); neg.: negative; pos. (+): weak positive; pos. (++): positive; pos. (+++): strong positive. #: Roche Cobas SARS-CoV-2 assay (E-gene, T2 target); ¶: TibMolbiol assay, E-gene target; \*: log<sub>10</sub> SARS-CoV-2 RNA copies/swab; §: only T1 CT value, T2 invalid due to suspected mutation within oligonucleotide binding region, VL not specified; <sup>f</sup>: including one false-positive on NMT and one on NP.

No invalid Ag-RDT results were observed on either NMT or NP samples. Four patients tested positive by NMT but not by NP sampling. One patient was positive by NP sampling only. The positive percent agreement was 93.5% (95% CI 79.3–98.2%), including one false positive result with NMT and one with NP. The negative percent agreement was 95.9% (95% CI 91.4–98.1%). Inter-rater reliability was high (kappa 0.95 for NMT; 0.98 for NP). In the semi-quantitative read-out of the test band intensity in double positive pairs, there was no remarkable difference (eight higher on NMT, nine higher on NP). A third reader was necessary for the agreement on the results of three tests for which the test band was very weak.

The STANDARD Q Ag-RDT with NMT sampling showed a sensitivity of 80.5% (33/41 PCR positives detected; 95% CI 66.0–89.8%) and specificity of 98.6% (95% CI 94.9–99.6%) compared to RT-PCR. The sensitivity with NP sampling was 73.2% (30/41 PCR positives detected; 95% CI 58.1–84.3%) and specificity was 99.3% (95% CI 96.0–100%). In patients with high viral load (>7.0 log<sub>10</sub> SARS-CoV2 RNA copies per swab), the sensitivity of the Ag-RDT with NMT sampling was 100% (19/19 PCR positives detected; 95% CI 83.9–100%) and 94.7% (18/19 PCR positives detected; 95% CI 76.4–99.7%) with NP sampling. In contrast, the Ag-RDT more frequently did not detect patients with lower viral load or with symptoms >7 days (table 1), as commonly observed in studies on Ag-RDTs [7, 8].

The strengths of the study are the standardised sampling methods, two independent blinded readers and an additional semi-quantitative assessment of Ag-RDT results. The cohort was representative, judging from the comparable sensitivity observed in the recent independent validation study of STANDARD Q (sensitivity 76.6%; 95% CI 62.8–86.4%) [9]. The study is limited as it was performed in a single centre. Theoretically, the previous NMT sample collection could have negatively influenced the test result of the NP sample in patients with a low viral load.

In conclusion, this study demonstrates that sensitivity of a WHO-listed SARS-CoV-2 Ag-RDT using professional nasal sampling kit is at least equal to that of NP sampling kit, although confidence intervals overlap. Of note, differences in the instructions for use of the test procedures could have contributed to different sensitivities. NMT sampling can be performed with less training, reduces patient discomfort, and enables scaling of antigen testing strategies. Additional studies of patient self-sampling should be considered to further facilitate scale-up of Ag-RDT testing [6].

**Andreas K. Lindner<sup>1,11</sup>, Olga Nikolai<sup>1,11</sup>, Chiara Rohardt<sup>1</sup>, Susen Burock<sup>2</sup>, Claudia Hülso<sup>1</sup>, Alisa Bölke<sup>1</sup>, Maximilian Gertler<sup>1</sup>, Lisa J. Krüger<sup>3</sup>, Mary Gaeddert<sup>3</sup>, Frank Tobian<sup>3</sup>, Federica Lainati<sup>3</sup>, Joachim Seybold<sup>4</sup>, Terry C. Jones<sup>5,6,7</sup>, Jörg Hofmann<sup>8</sup>, Jilian A. Sacks<sup>9</sup>, Frank P. Mockenhaupt<sup>1,12</sup> and Claudia M. Denkinger<sup>3,10,12</sup>**

<sup>1</sup>Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Tropical Medicine and International Health, Berlin, Germany. <sup>2</sup>Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Comprehensive Cancer Center, Berlin, Germany. <sup>3</sup>Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany. <sup>4</sup>Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Medical Directorate, Berlin, Germany. <sup>5</sup>Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany. <sup>6</sup>German Centre for Infection Research (DZIF), partner site Charité, Berlin, Germany. <sup>7</sup>Centre for Pathogen Evolution, Dept of Zoology, University of Cambridge, Cambridge, UK. <sup>8</sup>Labor Berlin – Charité Vivantes GmbH, Berlin, Germany. <sup>9</sup>Foundation for Innovative New Diagnostics, Geneva, Switzerland. <sup>10</sup>German Centre for Infection Research (DZIF), partner site Heidelberg, Heidelberg, Germany. <sup>11</sup>Authors contributed equally. <sup>12</sup>Authors contributed equally.

Correspondence: Claudia M. Denkinger, Division of Clinical Tropical Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany. E-mail: claudia.denkinger@uni-heidelberg.de

Received: 6 Dec 2020 | Accepted: 24 Jan 2021

This work is registered with the German Clinical Trial Registry (DRKS00021220). De-identified data that underlie the results in this paper, the study protocol and the analysis code will be made available to researchers who provide a sound proposal, to which all study sites agree to sharing the data, until 5 years after the date of publication. Proposals should be directed towards the corresponding author.

Acknowledgements: Heike Rössig, Mia Wintel, Franka Kausch, Elisabeth Linzbach, Katja von dem Busche, Stephanie Padberg, Melanie Bothmann, Zümüt Tuncer, Stefanie Lunow, Beate Zimmer, Astrid Barrera Pesek, Sabrina Pein, Nicole Buchholz, Verena Haack, Oliver Deckwart.

Author contributions: A.K. Lindner, L.J. Krüger, F. Lainati and C.M. Denkinger designed the study and developed standard operating procedures. A.K. Lindner and O. Nikolai implemented the study design, enrolled patients, performed laboratory work and led the writing of the manuscript. F.P. Mockenhaupt and J. Seybold coordinated and supervised the study site. C. Rohardt, S. Burock, C. Hülso and A. Bölke enrolled patients. M. Gertler coordinated the testing facility. M. Gaeddert and F. Tobian led the data analysis. T.C. Jones and J. Hofmann were responsible for PCR testing and contributed to the interpretation of the data. J.A. Sacks supported the study design setup and the interpretation of the data. All authors have reviewed the manuscript.

Conflict of interest: None declared.

Support statement: C.M. Denkinger reports grants from Foundation of Innovative New Diagnostics (FIND), and Ministry of Science, Research and Culture, State of Baden Wuerttemberg, Germany, to conduct the study. J.A. Sacks reports grants from UK Department of International Development (DFID, recently replaced by FCMO), World Health Organization (WHO) and Unitaid, to conduct the study. FIND supplied the test kits for the study. The study was supported by Heidelberg University Hospital and Charité University Hospital internal funds. Funding information for this article has been deposited with the Crossref Funder Registry.

## References

- 1 European Centre for Disease Prevention and Control. Options for the Use of Rapid Antigen Tests for COVID-19 in the EU/EEA and the UK. [www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigen-tests-covid-19-eeea-and-uk](http://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigen-tests-covid-19-eeea-and-uk) Date last accessed: 21 Nov 2020.
- 2 European Centre for Disease Prevention and Control. Surveillance of COVID-19 at Long-term Care Facilities in the EU/EEA. [www.ecdc.europa.eu/en/publications-data/surveillance-COVID-19-long-term-care-facilities-EU-EEA](http://www.ecdc.europa.eu/en/publications-data/surveillance-COVID-19-long-term-care-facilities-EU-EEA) Date last accessed: 21 Nov 2020.
- 3 US Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19. [www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html](http://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html) Date last accessed: 3 Jan 2021.
- 4 World Health Organization. Instructions and Requirements for Emergency Use Listing (EUL) Submission: *In vitro* Diagnostics Detecting SARS-CoV-2 Nucleic Acid and Rapid Diagnostics Tests Detecting SARS-CoV-2 Antigens. [https://extranet.who.int/pqweb/sites/default/files/documents/PQDx\\_347\\_NAT-antigen\\_instructions.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/PQDx_347_NAT-antigen_instructions.pdf) Version 4, June 2020. Date last accessed: 27 Nov 2020.
- 5 SD Biosensor. COVID-19 Ag STANDARDTM Q COVID-19 Ag Test 2020. <http://sdbiosensor.com/xs/product/7672> Date last accessed: 15 Oct 2020.
- 6 Lindner AK, Nikolai O, Kausch F, *et al.* Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab *versus* professional-collected nasopharyngeal swab. *Eur Respir J* 2021; 57: 2003961.
- 7 Berger A, Ngo Nsoga MT, Perez-Rodriguez FJ, *et al.* Diagnostic accuracy of two commercial SARS-CoV-2 antigen-detecting rapid tests at the point of care in community-based testing centers. *medRxiv* 2020; preprint [<https://doi.org/10.1101/2020.11.20.20235341>].
- 8 Schwob JM, Miauton A, Petrovic D, *et al.* Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial. *medRxiv* 2020; preprint [<https://doi.org/10.1101/2020.11.23.20237057>].
- 9 Krueger LJ, Gaeddert M, Koeppel L, *et al.* Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2. *medRxiv* 2020; preprint [<https://doi.org/10.1101/2020.10.01.20203836>].

Copyright ©The authors 2021.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)